Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 14/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501647 | 0.97 | PLA2G2A (0.41) | PLA2G2APPARG | |
| SCHEMBL6490815 | 0.92 | CYSLTR2 (0.41) | PLA2G2APPARG | |
| SCHEMBL6490551 | 0.89 | PLA2G2A (0.41) | PLA2G2AFFAR1PPARG | |
| SCHEMBL7194795 | 0.88 | PPARG (0.40) | PLA2G2APPARGMCL1 | |
| SCHEMBL6491561 | 0.86 | PLA2G4B (0.40) | PLA2G2AFFAR1FFAR4PPARG | |
| SCHEMBL6488344 | 0.86 | MCL1 (0.47) | PLA2G2AFFAR1FFAR4PPARGMCL1 | |
| SCHEMBL6501485 | 0.85 | PPARG (0.45) | PLA2G2AFFAR1FFAR4PPARGMCL1 | |
| SCHEMBL6492145 | 0.85 | PPARG (0.51) | PLA2G2AFFAR1FFAR4PPARGMCL1 | |
| SCHEMBL6489614 | 0.84 | PLA2G4B (0.41) | PPARG | |
| SCHEMBL6491422 | 0.83 | PPARG (0.51) | PLA2G2APPARGMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PLA2G2A 4801/4885FFAR1 1226/4885FFAR4 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.